Future Procurement Opportunity (FPO) – Supply of immune checkpoint inhibitors for the treatment of locally advanced/metastatic non-small cell lung cancer

Details

Tender Closed
RFx ID :	25820806
Tender Name :	Future Procurement Opportunity (FPO) – Supply of immune checkpoint inhibitors for the treatment of locally advanced/metastatic non-small cell lung cancer
Reference # :
Open Date :	Q2 2022
Indicative RFx Release Date  :	Q3 2022  [?]
Tender Type :	Future Procurement Opportunity (FPO)
Project Status :	Awaiting approval  [?]
Indicative Total Value :	$100M +  [?]
Tender Coverage :	Sole Agency  [?]
Categories :	51000000 - Drugs and Pharmaceutical Products
Regions:	New Zealand
Required Pre-qualifications :	None
Contact :	Pharmac Procurement Team procurement@pharmac.govt.nz .
Agency Address :
Related Tenders:	25993408 - RFP - Supply of immune checkpoint inhibitors for the treatment of locally advanced and metastatic non-small cell lung cancer

Pharmac will issue a competitive process for supply of immune checkpoint inhibitors (ICI’s) for the treatment of locally advanced/metastatic non-small cell lung cancer (NSCLC).

The anticipated outcome is a scenario where one or more ICI products would be awarded a period of Principal Supply exclusivity for listing in the Pharmaceutical Schedule, for one or more of the predefined patient groups; patients receiving ICIs for:
- first line 1L monotherapy;
- first line 1L combination therapy;
- second line 2L therapy.

This tender has been completed.

Date RFx was completed/updated: Wednesday, 13 July 2022 4:07 PM (Pacific/Auckland UTC+12:00)